Data as of Nov 26
| +2.84 / +0.69%|
The 20 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 413.00, with a high estimate of 480.00 and a low estimate of 315.00. The median estimate represents a -0.68% decrease from the last price of 415.84.
The current consensus among 22 polled investment analysts is to Buy stock in Regeneron Pharmaceuticals. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.